Seelos therapeutics announces completion of enrollment of its phase ii/iii trial of sls-005 in amyotrophic lateral sclerosis on the healey als platform

- the randomized, double-blind, placebo-controlled study is evaluating sls-005 in 160 patients over 24 weeks and seelos anticipates delivering topline data in the second half of 2023. - seelos will also enroll patients in an expanded access program that will be fully funded by a grant from the national institute of neurological disorders and stroke (ninds) under the accelerating access for critical therapies for als act (act for als).
SEEL Ratings Summary
SEEL Quant Ranking